Myriad Genetics traded at $5.46 this Monday February 2nd, decreasing $0.16 or 2.85 percent since the previous trading session. Looking back, over the last four weeks, Myriad Genetics lost 11.07 percent. Over the last 12 months, its price fell by 57.24 percent. Looking ahead, we forecast Myriad Genetics to be priced at 5.45 by the end of this quarter and at 4.96 in one year, according to Trading Economics global macro models projections and analysts expectations.
Myriad Genetics, Inc. (Myriad) is a genetic testing and precision medicine company. Myriad is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can progress patient care. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. The Company's products include myRisk, BRACAnalysis, BRACAnalysis CDx myChoice CDx, Prolaris, EndoPredict, Foresight and Prequel.